• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together more than 80 member organizations across the globe, united by a single vision: a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

What Guides Us

Our Vision

A world free of ALS/MND

Our Aspiration

To drive global collaboration

Our Reach

We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose

Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

Bring focus to quality of life

We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.

Include under-represented communities

By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.

Increase awareness of ALS/MND

By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.

Facilitate research coordination

By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.

Leverage collective capacity

By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.

Grow the community

By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Learn More

Alliance Strategy 2026–2028

Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Read the Strategy →

Annual Report 2024–2025

A review of the Alliance’s work and impact over the past year.

Read the Annual Report →

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Willi Klein, UK

    Willi Klein, UK

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • David Bishop, UK

    David Bishop, UK

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Mike Small, UK

    Mike Small, UK

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Susan Keldani, USA

    Susan Keldani, USA

  • Len Johnrose, England

    Len Johnrose, England

  • Mike Cels, Canada

    Mike Cels, Canada

  • Steve

    Steve

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • David Solomon, UK

    David Solomon, UK

  • Liam Dwyer, England

    Liam Dwyer, England

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Jean

    Jean
    jean

  • Orlando Ruiz, Colombia

    Orlando Ruiz, Colombia

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Glen Elison, USA

    Glen Elison, USA

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login